Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

Open access
Ahn, Myung‐Ju, Tsai, Chun‐Ming, Shepherd, Frances A., Bazhenova, Lyudmila, Sequist, Lecia V., Hida, Toyoaki, Yang, James C. H., Ramalingam, Suresh S., Mitsudomi, Tetsuya, Jänne, Pasi A., Mann, Helen, Cantarini, Mireille, Goss, Glenwood·2019·Cancer

Abstract

Background: Osimertinib is a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is selective for both EGFR‐TKI–sensitizing and T790M (threonine‐to‐methionine substitution at codon 790)‐resistance mutations. The authors present long‐term follow‐up data from a preplanned, pooled analysis of phase 2 studies, the AZD9291 First Time in Patients Ascending Dose Study (AURA) extension trial (clincialtrials.gov identifier NCT01802632) and the AURA2 trial (NCT02094261). Methods: Patients with centrally confirmed, T790M mutation‐positive, advanced non‐small cell lung cancer received osimertinib 80 mg once daily until disease progression or study discontinuation. Response was assessed by a blinded, independent, central review using Response Evaluation Criteria in Solid Tumors, version 1.1. The primary endpoint was the objective response rate. Results: In total, 411 patients received osimertinib (second line, 129 patients; third line or later, 282 patients). At the data cutoff date of November 1, 2016, the median treatment exposure was 16.4 months (range, 0‐29.7 months), the objective response rate was 66% (95% confidence interval [CI], 61%‐70%), the median response duration was 12.3 months (95% CI, 11.1‐13.8 months), and the median progression‐free survival was 9.9 months (95% CI, 9.5‐12.3 months). At the data cutoff date of May 1, 2018, 271 patients (66%) had died, and 140 patients (34%) had discontinued before death. The median overall survival was 26.8 months (95% CI, 24.0‐29.1 months); and the 12‐month, 24‐month, and 36‐month survival rates were 80%, 55%, and 37%, respectively. Grade ≥3 possibly causally related (investigator assessed) adverse events were reported in 65 patients (16%), and the most common were rash (grouped terms; 42%; grade ≥3, 1%) and diarrhea (39%; <1%). Conclusions: This pooled analysis represents the most mature clinical trial data for osimertinib in patients with pretreated, T790M‐positive, advanced non‐small cell lung cancer, further establishing osimertinib as a standard of care for this patient population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.31891

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 168

Metadata

Authors
Ahn, M., Tsai, C., Shepherd, F. A., Bazhenova, L., Sequist, L. V., Hida, T., Yang, J. C. H., Ramalingam, S. S., Mitsudomi, T., Jänne, P. A., Mann, H., Cantarini, M., & Goss, G.
Venue
Cancer
Publisher
Wiley
Published
2018-12-04
Volume
125
Issue
6
Pages
892-901
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2902378590
Cited by
168
References
13
FWCI
13.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies. https://app.cochat.ai/papers/10.1002/cncr.31891
The paper
Ahn, M., Tsai, C., Shepherd, F. A., Bazhenova, L., Sequist, L. V., Hida, T., Yang, J. C. H., Ramalingam, S. S., Mitsudomi, T., Jänne, P. A., Mann, H., Cantarini, M., & Goss, G. (2019). Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies. Cancer. https://doi.org/10.1002/cncr.31891

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.